



Pfizer Limited

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

August 23, 2017

The Department of Surveillance
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Scrip Symbol: PFIZER

Kind Attention: Mr. Avishkar Naik, Assistant Vice President

Dear Sir,

Re: Clarification/Confirmation on news item appearing in "Media/Publication"

This refers to your letter No. NSE/CM/Surveillance/6933 dated August 23, 2017 received by email at 11.41 am, seeking clarification on the recent news item which appeared in the Newspaper - Hindustan Times dated August 23, 2017 captioned "India grants Pfizer patent for pneumonia vaccine".

We wish to inform you as under:

The application for grant of patent in India for Prevenar 13 was filed by Wyeth LLC, USA. (a subsidiary of Pfizer Inc., USA) in the year 2007. This was subject to pre-grant opposition challenge before the Intellectual Property Office in India.

We understand that the pre-grant opposition has now been decided on merits by the Intellectual Property Office in India and a patent has been granted to Pfizer Inc., USA for Prevenar 13 in India.

Pfizer Limited has been marketing Prevenar 13 in India under a license given to it by Pfizer Inc., USA.

Trust this clarifies the matter. Rest assured, if and when Pfizer Limited makes any announcement regarding any material development in respect of our business, we will ensure that we continue to follow the mandated procedure of informing stock exchanges in a timely manner, so as to ensure uniform and simultaneous disclosure to all the investors.

Thanking you,

Yours truly,

For Pfizer Limited

Prajeet Nair

Company Secretary

CIN : L24231MH1950PLC008311

✉ contactus.india@pfizer.com

🌐 www.pfizerindia.com